DCVC H1 HA mRNA vaccine / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | N=10 ➔ 50

Enrollment change • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting | N=50 ➔ 10 | Trial completion date: May 2025 ➔ May 2026 | Trial primary completion date: May 2025 ➔ May 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Aug 2024 ➔ May 2025 | Trial primary completion date: Aug 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases